The current standard of care for the treatment of hepatitis C virus (HCV) infection is the combination of pegylated interferon and ribavirin. The interferon-based therapy is contraindicated in patients with HCV-associated thrombocytopenia. The pathogenesis of HCV-associated thrombocytopenia is still unclear. In this paper the main aspects of HCV-associated thrombocytopenia and alternative therapy with natural interferon (Alfaferone) are presented.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals.
BMC Gastroenterol
May 2023
Third Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, 2630 Sugitani, 930-0194, Japan.
Background: Thrombocytopenia due to hypersplenism is a major complication of hepatitis C virus (HCV)-associated cirrhosis. HCV eradication improves these complications in some patients, but the long-term effects of HCV eradication on these complications remain unclear, especially in patients treated with direct acting antivirals (DAAs). The aim was to evaluate long term changes in thrombocytopenia and leucopenia after HCV eradication with DAAs.
View Article and Find Full Text PDFImpact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection.
World J Hepatol
June 2022
Department of Community Medicine Research, National Research Center, Giza 12622, Dokki, Egypt.
Hepatitis C virus (HCV) is a common cause of liver disease and is associated with various extrahepatic manifestations (EHMs). This mini-review outlines the currently available treatments for HCV infection and their prognostic effect on hepatic manifestations and EHMs. Direct-acting antiviral (DAA) regimens are considered pan-genotypic as they achieve a sustained virological response (SVR) > 85% after 12 wk through all the major HCV genotypes, with high percentages of SVR even in advanced fibrosis and cirrhosis.
View Article and Find Full Text PDFPredictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia.
Ther Clin Risk Manag
February 2019
Tropical Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt,
Background And Aims: Thrombocytopenia is a common hematological abnormality observed in patients infected with hepatitis C virus (HCV). The use of eltrombopag has been approved for HCV-associated thrombocytopenia. This is the first study aiming to determine the predictive factors of response to eltrombopag therapy in patients with HCV-associated thrombocytopenia.
View Article and Find Full Text PDFSevere Thrombotic Complication of Eltrombopag in a Cirrhotic Patient.
ACG Case Rep J
January 2016
Division of Hepatology, Albert Einstein Medical Center, Philadelphia, PA.
We present a patient with hepatitis C virus (HCV) and cirrhosis who was treated with eltrombopag for idiopathic thrombocytopenic purpura and was incidentally found to have a right atrial thrombus with extension into the left internal jugular vein. Eltrombopag was discontinued and the patient was treated with thrombectomy and anticoagulation. Given the proposed use of eltrombopag in HCV-associated thrombocytopenia, we advise caution when treating cirrhotics who are at higher intrinsic risk of thrombosis.
View Article and Find Full Text PDFComparative efficacy and cost effectiveness of splenectomy and thrombopoietin prior to peginterferon and ribavirin therapy with compensatory cirrhosis associated with hepatitis C and thrombocytopenia.
Exp Ther Med
December 2015
Liver Fibrosis Diagnosis and Treatment Center, 302 Hospital of PLA, Beijing 100039, P.R. China.
The aim of the present study was to evaluate and compare the treatment efficacy and cost of two therapies, splenectomy and thrombopoietin, in order to optimize the treatment plans for patients with HCV-associated cirrhosis. A prospective randomized controlled trial was conducted on 69 patients with a platelet count <60,000/mm that were enrolled between 2009 and 2013, including 38 cases as the research group and 31 cases as the observed group. The study included two stages: A 4-week initial treatment and a 48-week antiviral treatment, during which a number of parameters were evaluated, including platelet count, liver stiffness measure, albumin, total bilirubin, alanine aminotranferase and treatment cost-effectiveness.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!